Routine board expansion with no financial or strategic implications. No trading action warranted — monitor next quarterly filing for any operational updates.
Price Chart
Executive Summary
Amphastar Pharmaceuticals appointed Anthony Pierce as a new independent Class III director, expanding the board from 10 to 11 members. This is a routine governance move with no material financial impact — no departures, no red flags, and no changes to strategy or operations.
Key Facts
- Board increased from 10 to 11 directors and appointed Anthony Pierce as a Class III director effective July 9, 2026.
- Mr. Pierce was determined to be independent under Nasdaq listing standards and was not assigned to any board committees.
- Compensation: $55,000 annual cash retainer (pro-rated) plus initial equity grant of $300,000 aggregate fair value (50% RSUs, 50% stock options), vesting on first anniversary.
- No departures, no red flags — this is a routine board expansion and independent director appointment.
Financial Impact
No material financial impact. Director compensation is standard: $55,000 annual cash retainer plus $300,000 initial equity grant.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (AMPH) — Batch item 1 | 0001104659-26-082772 |
| Document: 0001104659-26-082772-index-headers.html | 0001104659-26-082772 |
| Document: 0001104659-26-082772.txt | 0001104659-26-082772 |
| 8-K Filing (AMPH) — Batch item 4 | 0001104659-26-082772 |
| Document: 0001104659-26-082772-index-headers.html | 0001104659-26-082772 |
| Document: 0001104659-26-082772.txt | 0001104659-26-082772 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | Insider Cluster | $26.27 | awaiting T+60 | — | $25.32 (−3.62%) |
Sep 21, 2026 4w ago | 144 | $24.32 | awaiting T+60 | — | $25.32 (+4.11%) |
Aug 21, 2026 9w ago | Institutional Cluster | $21.60 | awaiting T+60 | — | $25.32 (+17.22%) |
Aug 12, 2026 10w ago | Insider Cluster | $20.18 | awaiting T+60 | — | $25.32 (+25.47%) |
Aug 11, 2026 10w ago | 144 | $20.31 | awaiting T+60 | — | $25.32 (+24.67%) |
Jul 13, 2026 15w ago | 8-K | $19.29 $25.91 | ▲ +34.32% | ▲ +30.32% | $25.32 (+31.26%) |
Jul 7, 2026 15w ago | 8-K | $18.88 $25.35 | ▼ −34.27% | ▼ −31.78% | $25.32 (−34.11%) |
Apr 13, 2026 27w ago | DEFA14A | $21.38 $19.02 | ▼ −11.04% | ▼ −19.56% | $25.32 (+18.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers